Tokyo, Feb 1, 2006 (JCN) - Astellas Pharma announced n January 31 that it has signed a licensing agreement with Ferring Pharmaceuticals on degarelix, Ferring's proprietary agent for treating prostate cancer. Under the agreement terms, Astellas Pharma will be licensed to exclusively develop and market the agent in Japan. Accordingly, Astellas will make upfront and milestone payments as well as royalties on product sales to Ferring Pharmaceuticals.
